|
1. |
BibliographyCurrent World Literature |
|
Current Opinion in Oncology,
Volume 11,
Issue 1,
1999,
Page 1-1
Preview
|
|
ISSN:1040-8746
出版商:OVID
年代:1999
数据来源: OVID
|
2. |
Advances in the biology and treatment of multiple myeloma |
|
Current Opinion in Oncology,
Volume 11,
Issue 1,
1999,
Page 3-3
Mary Varterasian,
Preview
|
|
摘要:
Advances in the understanding of the cellular and molecular derangements involved in the initiation and progression of multiple myeloma are beginning to be translated into novel therapeutic approaches. The myeloma stem cell has been under intense scrutiny regarding its normal B-cell counterpart. Oncogenes, tumor-suppressor genes, and cell-survival genes have all been found to be dysregulated in some myeloma patients. Growth factors, especially interleukin-6, appear to be critical for disease progression, and interruption of autocrine and paracrine loops has been achieved with resultant inhibition of myeloma cell growth. Mechanisms of drug resistance and the implications of the multidrug resistance phenotype are just beginning to be understood. High-dose therapeutic regimens with autologous peripheral blood stem cell or allogeneic bone marrow rescue are rigorously being studied with an emphasis on exploiting the graft-versus-myeloma effect. Pamidronate, a second-generation bisphosponate, has been shown to be effective at decreasing adverse skeletal events in patients with advanced myeloma. The topoisomerase 1 inhibitor, topotecan, has shown activity in an initial study.
ISSN:1040-8746
出版商:OVID
年代:1999
数据来源: OVID
|
3. |
The biology and treatment of acute progranulocytic leukemia |
|
Current Opinion in Oncology,
Volume 11,
Issue 1,
1999,
Page 9-9
James Slack,
Preview
|
|
摘要:
Acute progranulocytic leukemia (APL) is one of the most curable of all human cancers. Combination treatment with retinoic acid (RA) and anthracycline-based chemotherapy is safe and effective for the vast majority of patients, and several novel treatment approaches are under investigation for high-risk or relapsed patients. The APL-specific oncogenes PML-RARα and PLZF-RARα both bind nuclear corepressors and recruit histone deacetylase activity to promoters of RA target genes. The differential sensitivity of binding of these oncogenes to nuclear corepressors in the presence of RA appears to explain the resistance of PLZF-RARα–related APL to RA and at the same time explains the effectiveness of RA in PML-RARα–positive APL. Transcriptional repression of RA target genes, mediated by histone deacetylase activity, may thus be a key pathogenetic event in APL. Cure of the minority of resistant patients requires further refinement of current treatment approaches and appropriately timed incorporation of novel therapies, such as arsenic trioxide or histone deacetylase inhibitors.
ISSN:1040-8746
出版商:OVID
年代:1999
数据来源: OVID
|
4. |
Tailoring the treatment of acute myeloid leukemia |
|
Current Opinion in Oncology,
Volume 11,
Issue 1,
1999,
Page 14-14
Alan Burnett,
Preview
|
|
摘要:
For younger patients with acute myeloid leukemia (AML), the current priority is to prevent disease relapse. Intensification of induction has been shown to achieve this. Several randomized trials have been conducted to evaluate the role of autografting in AML. All trials reduce the risk of relapse but do not necessarily improve the survival, either because the competing effects of procedural mortality or salvage after relapse balance the benefits. Patients with different risk profiles may have different treatment plans. In older patients, progress is difficult to detect. Overcoming inherent drug resistance is of current interest, while improving supportive care by the routine use of growth factors has been disappointing.
ISSN:1040-8746
出版商:OVID
年代:1999
数据来源: OVID
|
5. |
The causes of acute leukemia |
|
Current Opinion in Oncology,
Volume 11,
Issue 1,
1999,
Page 20-20
Richard Severson,
Julie Ross,
Preview
|
|
摘要:
Although impressive biologic advances have increased understanding of leukemogenesis, we know little about the causes of the acute leukemias. Epidemiologic studies have focused primarily on children. Higher birth weight is associated with an increased risk of childhood acute leukemia. Several theories have been advanced that may account for these observations, and additional biologic studies are needed. Some epidemiologic studies suggest that the acute leukemias in children may have an infectious component. Again, further work, especially in the area of specific causative agents, is necessary. Another area for future epidemiologic study includes investigation of exposure to natural and synthetic DNA topoisomerase II inhibitors. Preliminary evidence suggests that exposure to these agents, which are found in certain foods and medications, may be related to the subsequent development of acute leukemia in infants. Curr Opin Oncol 1999, 11:20–24
ISSN:1040-8746
出版商:OVID
年代:1999
数据来源: OVID
|
6. |
From the bench to the bedside: clinical management of unusual tumors |
|
Current Opinion in Oncology,
Volume 11,
Issue 1,
1999,
Page 25-25
John Macdonald,
Preview
|
|
ISSN:1040-8746
出版商:OVID
年代:1999
数据来源: OVID
|
7. |
Diagnosis and therapy for pituitary tumors |
|
Current Opinion in Oncology,
Volume 11,
Issue 1,
1999,
Page 27-27
Erol Veznedaroglu,
Rocco Armonda,
David Andrews,
Preview
|
|
摘要:
This article focuses on developments in treatment options for pituitary adenomas. We review the literature on the advances in diagnosis and treatment modalities, including medical and surgical approaches. We also discuss conventional radiation and the recently proposed genetic treatments for pituitary tumors.
ISSN:1040-8746
出版商:OVID
年代:1999
数据来源: OVID
|
8. |
Recent advances in systemic therapy for gastrointestinal neuroendocrine tumors |
|
Current Opinion in Oncology,
Volume 11,
Issue 1,
1999,
Page 32-32
Robert Pelley,
Ronald Bukowski,
Preview
|
|
摘要:
Neuroendocrine tumors of the gastrointestinal tract are rare tumors which can be classified as amine precursor uptake and decarboxylation tumors (APU-Domas). Although the majority of clinically apparent tumors are malignant, they are frequently slow growing. Despite this characteristic, they may generate disabling hormonal syndromes requiring aggressive treatment to achieve palliation. Recent advances in understanding the pathophysiology of these tumors has led to better medical therapy with chemotherapeutic agents, somatostatin analogues, and biologic therapies. This review will update the recent efforts in systemic therapies of the gastrointestinal neuroendocrine tumors.
ISSN:1040-8746
出版商:OVID
年代:1999
数据来源: OVID
|
9. |
Embolization and chemoembolization therapy for neuroendocrine tumors |
|
Current Opinion in Oncology,
Volume 11,
Issue 1,
1999,
Page 38-38
Alan Venook,
Preview
|
|
摘要:
Neuroendocrine tumors, particularly those of gastrointestinal tract origin, have a predisposition for metastasizing to the liver. In such patients, the clinical course is often dominated by the hepatic disease, either because of hormone secretion or because of tumor bulk. Because the liver has a dual vascular supply and hepatic metastases derive the majority of blood from the hepatic artery, the regional delivery of chemotherapy can offer pharmacokinetic advantages over systemic administration. The hepatic artery is also a nonsurgical avenue for inducing selective metastasis ischemia by the embolization of tumor vessels. The combination of these two therapies, orchemoembolization, may provide additive benefits. Such an approach has been demonstrated to reduce tumor bulk, reduce hormone levels, and palliate the symptoms of many patients with liver-dominant neuroendocrine metastases. Embolization or chemoembolization is an appropriate modality for some patients with neuroendocrine tumors.
ISSN:1040-8746
出版商:OVID
年代:1999
数据来源: OVID
|
10. |
Advances in the pathogenesis and treatment of thyroid cancer |
|
Current Opinion in Oncology,
Volume 11,
Issue 1,
1999,
Page 42-42
Nader Hanna,
Patrick McGrath,
David Sloan,
Daniel Kenady,
Preview
|
|
摘要:
Thyroidectomy remains the mainstay of treatment for thyroid carcinoma. The extent of surgical resection, however, remains controversial as most patients will have excellent long-term prognosis and because some of the standard staging and prognostic information are not available at the time of surgical resection. The different staging and risk group definitions for thyroid carcinoma are not superior to the Tumor-Node-Metastasis classification of the American Joint Commission in Cancer (AJCC), which is universally available and accepted and should be used to report treatment outcomes. Recent advances in the molecular pathogenesis of thyroid malignancy will help identify high-risk patients who would benefit from aggressive surgical resection and adjuvant treatment.
ISSN:1040-8746
出版商:OVID
年代:1999
数据来源: OVID
|
|